Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

(2016) Stephen E. Gitelman et al.   DIABETOLOGIA

Type 1 diabetes vaccine candidates promote human Foxp3+Treg induction in humanized mice

(2016) Isabelle Serr et al.   Nature Communications

Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations

(2015) E Snarski et al.   BONE MARROW TRANSPLANTATION

Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes

(2015) M. J. Haller et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes

(2015) Maki Nakayama et al.   Current Diabetes Reports

Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

(2015) Aixin Yu et al.   DIABETES

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

(2015) Richard A. Insel et al.   DIABETES CARE

Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY)

(2015) Andrea K. Steck et al.   DIABETES CARE

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study

(2015) Polly J. Bingley et al.   Diabetes Technology & Therapeutics

The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study

(2015) Jeffrey P. Krischer et al.   DIABETOLOGIA

Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes

(2015) Ezio Bonifacio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

(2015) Mark R. Rigby et al.   JOURNAL OF CLINICAL INVESTIGATION

Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk

(2015) Xinli Hu et al.   NATURE GENETICS

Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects

(2015) Maki Nakayama et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

(2015) Jeffrey A. Bluestone et al.   Science Translational Medicine

Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study

(2015) Lucy A Truman et al.   BMJ Open

Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial

(2014) Itamar Raz et al.   DIABETES CARE

Hydrolyzed Infant Formula and Early β-Cell Autoimmunity

(2014) Mikael Knip et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

(2014) Michael J. Haller et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes

(2014) H Peter Chase et al.   PEDIATRIC DIABETES

Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes

(2014) L. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the trimolecular complex

(2013) Aaron W. Michels   CLINICAL IMMUNOLOGY

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

(2013) K. C. Herold et al.   DIABETES

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protege Trial

(2013) W. Hagopian et al.   DIABETES

B-Lymphocyte Depletion With Rituximab and  -Cell Function: Two-Year Results

(2013) M. D. Pescovitz et al.   DIABETES CARE

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

(2013) David M. Nathan et al.   DIABETES CARE

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

(2013) Tihamer Orban et al.   DIABETES CARE

Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children

(2013) Anette G. Ziegler et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

(2013) Antoinette Moran et al.   LANCET

Type 1 diabetes

(2013) Mark A Atkinson et al.   LANCET

Genetics of Type 1 Diabetes

(2013) J. A. Noble et al.   Cold Spring Harbor Perspectives in Medicine

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial

(2013) Stephen E Gitelman et al.   Lancet Diabetes & Endocrinology

Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study

(2012) Outi Vaarala et al.   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Prevention of Type 1 Diabetes in the Rat With an Allele-Specific Anti–T-Cell Receptor Antibody

(2012) Zhijun Liu et al.   DIABETES

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES

Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk

(2012) V. Parikka et al.   DIABETOLOGIA

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

(2012) K. C. Herold et al.   DIABETOLOGIA

GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus

(2012) Johnny Ludvigsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes: Diabetes Autoimmunity Study in the Young

(2011) A. K. Steck et al.   DIABETES CARE

Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up

(2011) H. Elding Larsson et al.   DIABETES CARE

Phase I (Safety) Study of Autologous Tolerogenic Dendritic Cells in Type 1 Diabetic Patients

(2011) N. Giannoukakis et al.   DIABETES CARE

Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope

(2011) Carolin Daniel et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structure-Based Selection of Small Molecules To Alter Allele-Specific MHC Class II Antigen Presentation

(2011) A. W. Michels et al.   JOURNAL OF IMMUNOLOGY

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

(2011) Diane K Wherrett et al.   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies

(2011) Christiane Winkler et al.   PEDIATRIC DIABETES

Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse

(2011) F. Crawford et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune intervention in type 1 diabetes

(2011) Aaron W. Michels et al.   SEMINARS IN IMMUNOLOGY

2011 Update

(2011) Aaron W. Michels et al.   Current Opinion in Endocrinology Diabetes and Obesity

Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I

(2010) E Snarski et al.   BONE MARROW TRANSPLANTATION

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential

(2010) M. Peakman et al.   DIABETES

Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity

(2010) Mikael Knip et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register

(2010) B. D. Stadinski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Type 1 Diabetes TrialNet-An International Collaborative Clinical Trials Network

(2009) Jay S. Skyler et al.   Annals of the New York Academy of Sciences

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

(2009) Kevan C. Herold et al.   CLINICAL IMMUNOLOGY

Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients

(2009) E. Vandemeulebroucke et al.   DIABETES & METABOLISM

C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus

(2009) Carlos E. B. Couri   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetics of Type 1A Diabetes

(2009) Patrick Concannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study

(2008) S. L. Thrower et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk: Analysis of the Type 1 Diabetes Genetics Consortium Families

(2008) H. Erlich et al.   DIABETES

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial

(2008) Kirsti Näntö-Salonen et al.   LANCET

Concordance for Islet Autoimmunity among Monozygotic Twins

(2008) Maria J. Redondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes

(2008) Johnny Ludvigsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results

(2008) Jeffrey L Mahon et al.   PEDIATRIC DIABETES